On September 28th, the launch of 2022-2023 "Shanghai Design 100+" and the theme forum of "Designing Innovative Cities" were held at the World Design Cites Conference. Mr. Wu Jincheng, Director of Shanghai Municipal Commission of Economy and Information Technology, Mr. Denise Bax, Director of UNESCO's Department of Cities and Events and Secretary General of the Creative Cities Network, and representatives of the award-winning companies attended the event. The Modular Vaccine Factory project in Morocco, designed and built by Pharmadule Morimatsu AB, was successfully selected as one of the "Shanghai Design 100+" for 2022-2023, and Mr. Li Daoquan, Senior Vice President of Morimatsu Life Sciences, attended the ceremony on behalf of the company and received the award.

Starting from Shanghai and facing the whole world, "Shanghai Design 100+" collects, displays and promotes excellent designs of the year, which is not only an important initiative for Shanghai to build a world-class "design capital", but also a stage for global design wisdom collision, exchange, transformation and sharing. This year, 2,542 excellent projects from 18 countries, including China, the United States, France, Italy and Spain, were declared. The final list was decided through the mechanism of "public voting + expert voting + industrial department voting", which combined 160,000 public votes, 100 Chinese and foreign experts' votes, and the votes of industrial departments of Shanghai and 16 districts. The Modular Vaccine Factory project designed and built by Pharmadule Morimatsu AB for a Moroccan client was selected as the winner, which is highly recognized by the government, the industry and the public for Morimatsu's design and construction strength.

This modular vaccine plant is a national project in Morocco and the largest modular vaccine plant exported from China to Africa, which can realize the aseptic filling of more than 20 kinds of vaccines, including COVID-19 vaccine, and contains 3 filling workshops, 3 packing workshops and QC labs, with a building area of about 10,000 square meters. This project fills the gap of local vaccine production in Africa, and is expected to meet more than 70% of Morocco's domestic vaccine demand in the future.

Morimatsu brings together the wisdom of innovation and design to empower companies in the vaccine field to accelerate their R&D and market launch for the benefit of patients worldwide. As a motivation for Morimatsu, we will continue to strive for new breakthroughs, and explore design, contributing to building Shanghai into a world-class design capital.

About Pharmadule Morimatsu AB

Pharmadule, a globally recognized leader in modular plant and solutions provision, has proudly completed 80 production facilities within the pharmaceutical and biopharmaceutical industries, along with over 300 successful engineering design and validation solutions since its establishment in 1986. With extensive experience in international project delivery and proper understanding of regulatory requirements in different regions, Pharmadule continues to provide a range of engineering and solutions to pharmaceutical and biopharmaceutical clients worldwide. After becoming a member of Morimatsu Group in 2011, Pharmadule Morimatsu AB perfectly integrates modular plants with process thanks to the strong combination, allowing the company to provide clients with higher-quality and faster turnkey solutions. Pharmadule Morimatsu AB has been selected by globally recognized pharmaceutical clients including Eli Lily, Merck, Baxter, GSK, Genentech, AZ and Lonza, to facilitate quicker and more efficient patient treatment plans.

About Morimatsu LifeSciences

Morimatsu LifeSciences is a subsidiary of Morimatsu International Holdings Limited (Morimatsu International, stock code: 2155.HK), covering pharmaceutical, biopharmaceutic, FMCG, cosmetics, electronic chemicals and other industries, provides clients with "core equipment/Machinery + Value added + digitalized intelligence overall Plant Solutions and Service" (" MVP Solutions & Service"), mainly including Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., LTD., Morimatsu (Suzhou) LifeSciences Co., LTD., Shanghai Morimatsu Biotechnology Co., LTD., and Pharmadule Morimatsu AB., Morimatsu Pharmadule (Singapore) Private Limited as well as their subsidiaries. Morimatsu LifeSciences is focusing on the research and development, manufacturing, and sales of products in related fields.

Morimatsu has grown and become diversified multinational corporation today with vast experiences and professional know-how knowledge in fields of process engineering equipment as well as modular engineering solutions. Our company has established long-term collaboration relationships with numerous well-known global corporations. We have subsidiaries in Sweden, Italy, US, India, Singapore, Malaysia, as well as large scale manufacturing facilities in Asia. So far, Morimatsu has delivered projects to more than 40 countries/regions in the world, gained an excellent industrial reputation globally.

Forward-looking Statements

The information contained in this press release may contain certain forward-looking statements. These statements are inherently subject to considerable risk and uncertainty. When used in connection with the Company, the words "anticipate," "believe," "forecast," "expect," "intend," and other similar expressions are intended to indicate that they are forward-looking statements. The Company undertakes no obligation to update these predictive statements from time to time.

These forward-looking statements are based on the current views, assumptions, expectations, estimates, projections and understandings of the Company's management regarding future events at the time the statements were made. These statements are not guarantees of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements, subject to future changes and developments in our business, competitive environment, political, economic, legal and social conditions.